TRP 005Alternative Names: TRP-005
Latest Information Update: 08 Dec 2015
At a glance
- Originator Turing Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain disorders
Most Recent Events
- 08 Dec 2015 Preclinical trials in Brain disorders in USA (unspecified route) prior to December 2015 (Turing Pharma Pipeline, December 2015)